Disease progression in patients with virological suppression in response to HAART is associated with the degree of immunological response
- 14 February 2006
- journal article
- Published by Wolters Kluwer Health in AIDS
- Vol. 20 (3) , 371-377
- https://doi.org/10.1097/01.aids.0000196180.11293.9a
Abstract
Objective: To determine if immunological response is associated with disease progression in patients with virological suppression after initiating HAART. Design: A cohort study of 1084 treatment-naive participants in the British Columbia HIV/AIDS Drug Treatment Program who had achieved viral loads < 500 copies/ml at 3–9 months after initiating triple-drug therapy. Methods: Cox proportional hazards was used to model the association with disease progression of baseline variables, change in CD4 cell counts and CD4 cell count strata at 6 months. Logistic regression analysis was used to examine associations with two definitions of poor immunological response. Results: Patients were followed for a median of 51.4 months. In univariate analyses, increases in CD4 cell counts of < 25 cells/μl and absolute CD4 cell counts of < 200 cells/μl were associated with an increased risk of death or new AIDS events. Two mulitivariate models, one including baseline CD4 cell count and change in CD4 cell count from baseline and the other including only absolute CD4 cell counts at 6 months, were found to predict disease progression in this setting. Increases in CD4 cell count of < 25 cells/μl were associated with increasing age and inversely associated with low baseline CD4 cell counts, high baseline viral loads and good adherence to therapy. CD4 cell counts of < 200 cells/μl at 6 months were associated with low baseline CD4 cell counts and having AIDS at baseline. Conclusion: Patients with virological suppression are still at risk for HIV disease progression if adequate immunological responses are not achieved.Keywords
This publication has 16 references indexed in Scilit:
- Long‐Term Clinical Outcome of Human Immunodeficiency Virus–Infected Patients with Discordant Immunologic and Virologic Responses to a Protease Inhibitor–Containing RegimenThe Journal of Infectious Diseases, 2001
- Clinical Outcome of Patients with HIV-1 Infection according to Immunologic and Virologic Response after 6 Months of Highly Active Antiretroviral TherapyAnnals of Internal Medicine, 2000
- Full suppression of viral load is needed to achieve an optimal CD4 cell count response among patients on triple drug antiretroviral therapyAIDS, 2000
- Suppression of Plasma Virus Load below the Detection Limit of a Human Immunodeficiency Virus Kit Is Associated with Longer Virologic Response than Suppression below the Limit of QuantitationThe Journal of Infectious Diseases, 1999
- Clinical progression and virological failure on highly active antiretroviral therapy in HIV-1 patients: a prospective cohort studyThe Lancet, 1999
- Suppression of plasma viral load below 20 copies/ml is required to achieve a long-term response to therapyAIDS, 1998
- Discrepant responses to triple combination antiretroviral therapy in advanced HIV diseaseAIDS, 1998
- A Randomized, Double-blind Trial Comparing Combinations of Nevirapine, Didanosine, and Zidovudine for HIV-Infected PatientsJAMA, 1998
- Randomised placebo-controlled trial of ritonavir in advanced HIV-1 diseaseThe Lancet, 1998
- A Controlled Trial of Two Nucleoside Analogues plus Indinavir in Persons with Human Immunodeficiency Virus Infection and CD4 Cell Counts of 200 per Cubic Millimeter or LessNew England Journal of Medicine, 1997